Signal Genetics Files for $25M IPO | GenomeWeb

NEW YORK (GenomeWeb News) – Signal Genetics plans to offer 2,272,000 shares of common stock at $10 to $12 per share through its initial public offering, the cancer molecular diagnostics company said in a prospectus filing with the US Securities and Exchange Commission.

Assuming an average price of $11 per share, the company expects to raise about $25 million through the offering, if the underwrites exercise their full over-allotment option for an additional 340,800 shares.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.